The pitch from China’s MGI Tech to US labs seems appealing: Its DNA sequencing machines can decode a genome for around $100, an important benchmark in the world of high-cost research.
But more than a year after its US launch, MGI has found a chilly reception in a market that continues to be dominated by Illumina, Endpoints News learned through a review of early sales data and conversations with industry experts.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.